摘要:
Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Privided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
摘要:
The disclosure relates to peptides that can interact with RIP homotypic interaction motif (RHIM) proteins/peptides. These peptides also contain a RHIM motif which has an evolutionary conserved core tetrad sequence (V/I)-Q-(V/I/L/C)-G found in RIPK1, RIPK3 and their orthologues, such as DAI and TRIP. The peptide-peptide RHIM motif interaction causes multimerisation, amyloid formation and activation of the NLRP3 inflammasome. This in turn causes an artificial or temporary induction of inflammatory cell death, enhances the level of inflammatory mediators, such as IL-Ιβ, and results in an increase of inflammatory cell infiltrate, such as CD8+ T cells, into the tissue space. The therapeutic application is for tumour suppression, pathogenic regression and enhancing the immune response to vaccination.
摘要:
The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.
摘要:
Methods for treating inflammation, including allergic inflammation, lymphocyte-driven inflammation, and inflammatory conditions such as allergic asthma and allergic lung inflammation, using inhibitors of the polycomb repressive complex 2 (PRC2) methyltransferase enhancer of zeste homolog 2 (Ezh2) are provided.
摘要:
A system, method, apparatus and diagnostic test for Plasmodium vivax , to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites ("dormant" liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.
摘要:
In one aspect, the present invention relates to the crystal structure of Plasmodium vivax plasmepsin V in complex with an inhibitor, and to methods of using the crystal structure and related structural information to identify, design and/or screen for inhibitors or redesign known inhibitors that interact with and/or modulate plasmepsin V activity. In another aspect, the present invention relates to a class of compounds based on the inhibitor useful in the treatment of malaria.
摘要:
A method for identifying the level of T-regulatory cell activity in a test biological sample comprising immune cells, the method comprising screening a test sample for the methylation profiles of a pre-selected genetic locus/loci selected from the list consisting of: (i) at least one genetic locus or at least two genetic Loci defined m one or more of Table 1 to Table 5; (ii) at least one genetic locus or at least two genetic loci defined in one or more of Table 6 to Table 10; and (iii) at least two genetic loci defined in one or more of Table 1 to Table 5, and one or more of Table 6 to Table 10; and determining the degree of concordance between the test methylation profiles and a reference methylation profile, wherein the degree of concordance identifies the level of T-regulatory cell activity in the sample.
摘要:
The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.
摘要:
The present invention relates to substituted sulfone-containing tricyclic compounds and analogues thereof which inhibit Bak-mediated apoptosis. The invention further relates to pharmaceutical compositions comprising a compound of the present invention and to methods of inhibiting a Bak-mediated apoptotic pathway and Bak-mediated apoptosis in a cell.
摘要:
The present disclosure generally relates to antibodies that are capable of enhancing an immune response to an antigen and to methods of using such antibodies. In one example, the present disclosure generally relates to antibodies that are capable of binding to the cell surface membrane-anchored glycoprotein CD52 or a soluble fragment thereof. Exemplary methods of using such antibodies include enhancing a subject's immune response to an antigen, determining the level of a subject's immune response to an antigen, and other methods disclosed herein.